A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome
NCT ID: NCT00578825
Last Updated: 2013-08-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
340 participants
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b
NCT02845843
Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection
NCT04261907
PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
NCT05780541
A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia
NCT04255017
To Evaluate SSD8432/Ritonavir in Adults With COVID-19
NCT05373433
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lopinavir / Ritonavir plus Ribavirin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Authority, Hong Kong
OTHER_GOV
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wai Cho Yu, Dr
Role: PRINCIPAL_INVESTIGATOR
Department of Medicine & Geriatrics, Princess Margaret Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Health
Hong Kong, , China
Kowloon Hospital
Hong Kong, , China
Prince of Wales Hospital
Hong Kong, , China
Princess Margaret Hospital
Hong Kong, , China
Queen Mary Hospital
Hong Kong, , China
The Chinese University of Hong Kong
Hong Kong, , China
The University of Hong Kong
Hong Kong, , China
Tuen Mun Hospital
Hong Kong, , China
United Christian Hospital
Hong Kong, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HARECCTR0500028
Identifier Type: -
Identifier Source: secondary_id
NTWC/CREC/349/05
Identifier Type: -
Identifier Source: secondary_id
KW/FR/04-009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.